Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-05-31
2008-09-23
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800
Reexamination Certificate
active
07427598
ABSTRACT:
The present invention provides methods for improving performance (e.g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.
REFERENCES:
patent: 4587046 (1986-05-01), Goodman et al.
patent: 5767240 (1998-06-01), Brenneman et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6613740 (2003-09-01), Gozes et al.
patent: 6933277 (2005-08-01), Brenneman et al.
patent: 2004/0053313 (2004-03-01), Gozes et al.
patent: 1 206 489 (2004-05-01), None
patent: WO 92/18140 (1992-10-01), None
patent: WO 96/11948 (1996-04-01), None
patent: WO 98/35042 (1998-08-01), None
patent: WO 98/35042 (1998-08-01), None
patent: WO 00/27875 (2000-05-01), None
patent: WO 00/53217 (2000-09-01), None
patent: WO 01/12654 (2001-02-01), None
Bassan et al. 1999. Journal of Neurochemistry 72:1283-1293.
Voet 1995. Biochemistry, Second Edition, p. 67.
Spong 1999. Society for Neuroscience Abstracts 25(1):405-9.
Guptasarma 1992. FEBS Letters 310:205-210.
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides, vol. 71, No. 2, (Aug. 15, 1997).
Bassan, M. et al. “Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry, vol. 72, pp. 1283-1293 (1999).
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts, vol. 23, Part 1, p. 1043 (1998).
Brenneman, D.C. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation, vol. 97, pp. 2299-2307 (1996).
Brenneman et al. “Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide.”Nature335:636 (1988).
Brenneman et al. “N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures”Dev. Brain Res. 51:63 (1990).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Brenneman, D.E. et al. “Activity-Dependent Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics, vol. 285, pp. 619-627 (1998).
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation, vol. 99, pp. 28377-2841 (1997).
GenBank Accession No. AB018327 from the DNA Data Bank of Japan (DDBJ) (released Nov. 17, 1998).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience Letters, Supplement 48 S1-S60, p. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2249 (1997).
Glazner, G.W. et al. “Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth.”Anat. Embryol. 200:65-71 (1999).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience, vol. 7, pp. 235-244 (1996).
Gozes, I. et al. “Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology, vol. 134, pp. 2125 (1994).
Gozes, I. et al. “Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics, vol. 273, pp. 161-167 (1995).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci. USA, vol. 93, pp. 427-432 (1996).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity.”Developmental Brain Research, vol. 99, pp. 167-175 (1997).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience Letters, Supplement 48 S1-S60, p. S21 (1997).
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology, vol. 33, pp. 329-342 (1997).
Gozes, I. et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Gozes, et al., “A Novel Signaling Molecule for Neuropeptide Action: Activity-dependent Neuroprotective Protein”; Annals of the New York Academy of Sciences, 897:125-135 (1999).
Gozes, I. et al. “Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze”Journal of Pharmacology and Experimental Therapeutics, vol. 293, pp. 1091-1098 (2000).
Gressens, P. et al. “Growth Factor Function of Vasoactive Intestinal Peptide in Whole Cultured Mouse Embryos.”Nature362:155-58 (1993).
Hannigan, J.H. and Berman, R.F. “Amelioration of Fetal Alcohol-Related Neurodevelopmental Disorders in Rats: Exploring Pharmacological and Environmental Treatments.”Neurotoxicol. &Teratol. 22(1):103-111 (2000).
Hill, J.M. et al. “Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antiseum to Activity-Dependent Neurotrophic Factor (ADNF).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Lilling, G. et al. “Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist.”Journal of Molecular Neuroscience, vol. 5, pp. 231-239 (1995).
Mahato et al. “Development of Targeted Delivery Systems for Nucleic Acid Drugs.”J. of Drug Targeting4(6):337-357 (1997) [Abstract].
McKune, S.K. et al. “Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2249 (1997).
Nagase, et al., “Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro”; DNA Research 5:5:277-286 (1998).
Nelbock, P. et al. A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator.Science, vol. 248, pp. 1650-1653 (1990).
Oberdoester, J. et al. “The Effects of Ethanol on Neuronal Cell Death: Implication for the Fetal Alcohol Syndrome.”FASEB Journal12(4):A134 (Mar. 17, 1998).
Pelsman, A. et al. “In Vitro Degeneration of Down Syndrome neurons is Prevented by Acti
Brenneman Douglas
Gozes Illana
Spong Catherine Y.
Kolker Daniel E.
Ramot at Tel-Aviv University Ltd.
The United States of Americas as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Post-natal administration of activity-dependent neurotrophic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Post-natal administration of activity-dependent neurotrophic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Post-natal administration of activity-dependent neurotrophic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3966466